As of April 16, 2025, Madrigal Pharmaceuticals (MDGL) has a market cap of $7.09 billion USD. According to our data, Madrigal Pharmaceuticals is ranked No.2071 in global market value.
Year | Market Cap | %Change |
---|---|---|
Apr 16, 2025 | $7.09 B |
5.35%
|
Dec 31, 2024 | $6.73 B |
33.36%
|
Dec 29, 2023 | $5.05 B |
-20.28%
|
Dec 30, 2022 | $6.33 B |
242.52%
|
Dec 31, 2021 | $1.85 B |
-23.77%
|
Dec 31, 2020 | $2.42 B |
22.02%
|
Dec 31, 2019 | $1.99 B |
-19.17%
|
Dec 31, 2018 | $2.46 B |
22.80%
|
Dec 29, 2017 | $2.00 B |
516.04%
|
Dec 30, 2016 | $0.32 B |
21.63%
|
Dec 31, 2015 | $0.27 B |
-86.79%
|
Dec 31, 2014 | $2.02 B |
-49.43%
|
Dec 31, 2013 | $4.00 B |
-41.91%
|
Dec 31, 2012 | $6.89 B |
93.15%
|
Dec 30, 2011 | $3.56 B |
-23.69%
|
Dec 31, 2010 | $4.67 B |
20.95%
|
Dec 31, 2009 | $3.86 B |
-17.32%
|
Dec 31, 2008 | $4.67 B |
-8.66%
|
Dec 31, 2007 | $5.11 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
![]() Gilead Sciences
GILD
|
$131.74 B |
-0.002 M
|
![]() USA
|
![]() Viking Therapeutics
VKTX
|
$2.59 B |
-0.000 M
|
![]() USA
|
![]() Galmed Pharmaceuticals
GLMD
|
$3.18 M |
0.000 M
|
![]() Israel
|
![]() Genfit
GNFT
|
$0.18 B |
0.000 M
|
![]() France
|
![]() Akero Therapeutics
AKRO
|
$3.03 B |
0.000 M
|
![]() USA
|
![]() 89bio
ETNB
|
$0.88 B |
-0.000 M
|
![]() USA
|
![]() Hepion Pharmaceuticals
HEPA
|
$3.84 M |
3.463 M
|
![]() USA
|
![]() Pfizer
PFE
|
$127.27 B |
-0.003 M
|
![]() USA
|
![]() AstraZeneca
AZN
|
$210.42 B |
-0.005 M
|
![]() UK
|
![]() Novartis
NVS
|
$217.12 B |
0.003 M
|
![]() Switzerland
|
![]() Bristol-Myers Squibb
BMY
|
$101.74 B |
-0.001 M
|
![]() USA
|
![]() Merck
MRK
|
$197.26 B |
0.003 M
|
![]() USA
|
![]() Eli Lilly
LLY
|
$679.94 B |
-0.022 M
|
![]() USA
|
Market Cap | = | MDGL Stock Price | * | MDGL Shares Outstanding |
= | $321.10 | * | 22.08 M | |
= | $7.09 B |